<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896557</url>
  </required_header>
  <id_info>
    <org_study_id>0136/11</org_study_id>
    <nct_id>NCT01896557</nct_id>
  </id_info>
  <brief_title>Ranitidin Versus Omeprazole in Patients Taking Clopidogrel</brief_title>
  <official_title>Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous reports have shown a possible drug interaction between clopidogrel and proton pump
      inhibitors (PPI´s), which could result in increased number of adverse cardiovascular events
      among patients on dual antiplatelet therapy(DAPT). Because of this, ranitidin has been
      proposed as an alternative drug to PPI´s for prophylaxis of gastrointestinal bleeding in
      patients who need DAPT. The study´s aim is to test the hypothesis that ranitidin doesn´t have
      any influence on clopidogrel pharmacodynamic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population: 100 patients with Stable Coronary Artery Disease from Heart Institute

      Inclusion Criteria:

        -  Age &gt; 18 years old

        -  Coronary artery disease, defined as previous myocardial infarction and/or coronary
           angioplasty and/or Coronary Artery Bypass Graft (CABG) surgery and/or coronariography
           showing obstruction of at least 50 % in one of major epicardial vessels

        -  Treatment with Acetylsalicylic Acid (ASA) 100 mg/day

      Exclusion Criteria:

        -  Use in the last 7 days of oral anticoagulant or any other antiplatelet drug beside ASA

        -  Previous utilization of PPI or ranitidine in the last 7 days before randomization

        -  Active bleeding

        -  Pregnancy or woman of childbearing age without contraceptive method

        -  Hemoglobin &lt; 10 g/dL or hematocrit &lt; 30 %, hematocrit &gt; 50 %, platelets &lt; 100.000/mm3 or
           &gt; 500.000/mm3; creatinin clearance &lt; 50 ml/minute

        -  Percutaneous coronary intervention (PCI) on the last 30 days before randomization (or
           PCI on the last year when drug-eluted stents are used); CABG surgery on the last 90
           days; acute coronary syndrome on the last 60 days

        -  Active malignant neoplasm

        -  Active peptic ulcer disease on the last 60 days or upper gastrointestinal bleeding any
           time in life

        -  Known allergy to the drugs clopidogrel, ranitidine or omeprazole

        -  Refuse to participate in the study]

      Methodology: The study has a double-blind, double-dummy prospective design. Clopidogrel
      action is evaluated by platelet function tests: VerifyNow, bioimpedance aggregometry and
      Platelet Function Analyzer-100 (PFA-100). The patients have measurements of platelet function
      on three moments: before starting clopidogrel; 1 week after DAPT with clopidogrel (without
      loading dose) plus ASA; and after 1 week of randomization to ranitidin 150 mg bid or
      omeprazole 20 mg bid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.</measure>
    <time_frame>One week after drug exposure (omeprazole/ranitidine); 2 weeks after baseline</time_frame>
    <description>One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in P2Y12 Reactivity Units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.</measure>
    <time_frame>One week after drug exposure (omeprazole/ranitidine); 2 weeks after baseline</time_frame>
    <description>One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in percent Inhibition of Platelet Aggregation (IPA) from baseline. IPA was calculated as Observed Platelet aggregability - Platelet aggregability at baseline divided by Platelet aggregability at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Primary Outcome With Other Two Methods of Platelet Aggregability: PFA-100 and Bioimpedance Aggregometry</measure>
    <time_frame>1 week after drug exposure</time_frame>
    <description>After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by two other methods: PFA-100 (Siemens-USA) and bioimpedance aggregometry.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparing the Main Outcome on Pre-specified Subgroups</measure>
    <time_frame>1 week after drug exposure</time_frame>
    <description>The main outcome will be compared on pre-specified subgroups:
elderly (age &gt; 65 yrs-old) versus non-elderly
male versus female
smoking versus non-smoking patients
obese (BMI &gt; 30 kg/m2) versus non-obese
diabetic versus non-diabetic
patients in use or not in use of statins
presence or not of genetic polymorphisms on cytochrome 2C19.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ranitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.</description>
    <arm_group_label>omeprazole</arm_group_label>
    <other_name>Peprazol</other_name>
    <other_name>Losec</other_name>
    <other_name>PPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine</intervention_name>
    <description>Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.</description>
    <arm_group_label>ranitidine</arm_group_label>
    <other_name>Antak</other_name>
    <other_name>H2 receptor blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel added to ASA therapy at the first medical visit</description>
    <arm_group_label>omeprazole</arm_group_label>
    <arm_group_label>ranitidine</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>ADP receptor blocker</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Coronary artery disease, defined as previous myocardial infarction and/or coronary
             angioplasty and/or CABG surgery and/or coronariography showing obstruction of at least
             50 % in one of major epicardial vessels

          -  Treatment with Acetylsalicylic Acid (ASA) 100 mg/day

        Exclusion Criteria:

          -  Use on the last 7 days of any other antiplatelet drug beside ASA or oral anticoagulant

          -  Previous utilization of PPI or ranitidine in the last 7 days before randomization

          -  Any active bleeding

          -  Pregnancy or woman of childbearing age without contraceptive method

          -  Hemoglobin &lt; 10 g/dL or hematocrit &lt; 30 %, hematocrit &gt; 50 %, platelets &lt; 100.000/mm3
             or &gt; 500.000/mm3; creatinin clearance &lt; 50 ml/minute

          -  Percutaneous coronary intervention (PCI) on the last 30 days before randomization (or
             PCI on the last year when drug-eluted stents are used); CABG surgery on the last 90
             days; acute coronary syndrome on the last 60 days

          -  Active malignant neoplasm

          -  Active peptic ulcer disease on the last 60 days or upper gastrointestinal bleeding any
             time in life

          -  Known allergy to the drugs clopidogrel, ranitidine or omeprazole

          -  Refuse to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José C Nicolau, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Acute Coronary Care Unit</affiliation>
  </overall_official>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <results_first_submitted>May 28, 2015</results_first_submitted>
  <results_first_submitted_qc>May 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>omeprazole</keyword>
  <keyword>ranitidin</keyword>
  <keyword>interaction</keyword>
  <keyword>aggregability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omeprazole</title>
          <description>Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
omeprazole: Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.</description>
        </group>
        <group group_id="P2">
          <title>Ranitidine</title>
          <description>Ranitidine 150 mg BID oral route was added to clopidogrel.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Clopidogrel Alone</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Clopidogrel + GI Protector</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>low adherence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reading error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omeprazole</title>
          <description>Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
omeprazole: Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.</description>
        </group>
        <group group_id="B2">
          <title>Ranitidine</title>
          <description>Ranitidine 150 mg BID oral route was added to clopidogrel.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age in years</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="10.9"/>
                    <measurement group_id="B2" value="62.5" spread="8.9"/>
                    <measurement group_id="B3" value="62.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.</title>
        <description>One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in P2Y12 Reactivity Units.</description>
        <time_frame>One week after drug exposure (omeprazole/ranitidine); 2 weeks after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole</title>
            <description>Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
omeprazole: Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>Ranitidine</title>
            <description>Ranitidine 150 mg BID oral route was added to clopidogrel.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.</title>
          <description>One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in P2Y12 Reactivity Units.</description>
          <units>P2Y12 Reactivity Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.54" spread="72.28"/>
                    <measurement group_id="O2" value="153.61" spread="70.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.</title>
        <description>One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in percent Inhibition of Platelet Aggregation (IPA) from baseline. IPA was calculated as Observed Platelet aggregability - Platelet aggregability at baseline divided by Platelet aggregability at baseline.</description>
        <time_frame>One week after drug exposure (omeprazole/ranitidine); 2 weeks after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole</title>
            <description>Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
omeprazole: Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>Ranitidine</title>
            <description>Ranitidine 150 mg BID oral route was added to clopidogrel.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.</title>
          <description>One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in percent Inhibition of Platelet Aggregation (IPA) from baseline. IPA was calculated as Observed Platelet aggregability - Platelet aggregability at baseline divided by Platelet aggregability at baseline.</description>
          <units>Inhibition of Platelet Aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="33.1"/>
                    <measurement group_id="O2" value="30.1" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Primary Outcome With Other Two Methods of Platelet Aggregability: PFA-100 and Bioimpedance Aggregometry</title>
        <description>After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by two other methods: PFA-100 (Siemens-USA) and bioimpedance aggregometry.</description>
        <time_frame>1 week after drug exposure</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Comparing the Main Outcome on Pre-specified Subgroups</title>
        <description>The main outcome will be compared on pre-specified subgroups:
elderly (age &gt; 65 yrs-old) versus non-elderly
male versus female
smoking versus non-smoking patients
obese (BMI &gt; 30 kg/m2) versus non-obese
diabetic versus non-diabetic
patients in use or not in use of statins
presence or not of genetic polymorphisms on cytochrome 2C19.</description>
        <time_frame>1 week after drug exposure</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omeprazole</title>
          <description>Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
omeprazole: Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.</description>
        </group>
        <group group_id="E2">
          <title>Ranitidine</title>
          <description>Ranitidine 150 mg BID oral route was added to clopidogrel.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>Dyspepsia after clopidogrel was introduced without GI protector</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Remo Holanda de Mendonca Furtado</name_or_title>
      <organization>Heart Institute of University of Sao Paulo Medical School</organization>
      <phone>+5511 26615058</phone>
      <email>remo_holanda@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

